CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene After Haploidentical Stem Cell Transplantation.

Trial Profile

CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene After Haploidentical Stem Cell Transplantation.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Rivogenlecleucel (Primary) ; Rimiducid
  • Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms CASPALLO
  • Most Recent Events

    • 25 Sep 2014 Planned End Date changed from 1 Apr 2026 to 1 Jul 2026 as reported by ClinicalTrials.gov record.
    • 05 Feb 2014 Planned End Date changed from 1 Aug 2028 to 1 Apr 2026 as reported by ClinicalTrials.gov.
    • 13 Apr 2012 Planned end date changed from 1 Aug 2013 to 1 Aug 2028 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top